[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,650,304
  • Shares Outstanding, K 198,173
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,131 M
  • EBIT $ -1,182 M
  • EBITDA $ -1,194 M
  • 60-Month Beta 1.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 16.77

Options Overview Details

View History
  • Implied Volatility 49.01% (-0.78%)
  • Historical Volatility 107.20%
  • IV Percentile 33%
  • IV Rank 12.56%
  • IV High 129.42% on 04/10/26
  • IV Low 37.46% on 09/18/25
  • Expected Move (DTE 20) 10.07 (7.44%)
  • Put/Call Vol Ratio 1.32
  • Today's Volume 2,545
  • Volume Avg (30-Day) 10,442
  • Put/Call OI Ratio 1.41
  • Today's Open Interest 131,001
  • Open Int (30-Day) 126,223
  • Expected Range 125.23 to 145.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.83
  • Number of Estimates 10
  • High Estimate $-1.73
  • Low Estimate $-1.92
  • Prior Year $-1.13
  • Growth Rate Est. (year over year) -61.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
91.52 +47.84%
on 03/30/26
155.70 -13.10%
on 04/16/26
+39.78 (+41.65%)
since 03/24/26
3-Month
91.52 +47.84%
on 03/30/26
155.70 -13.10%
on 04/16/26
+17.67 (+15.02%)
since 01/23/26
52-Week
34.00 +297.94%
on 08/07/25
155.70 -13.10%
on 04/16/26
+96.72 (+250.70%)
since 04/24/25

Most Recent Stories

More News
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 135.30 (+0.61%)
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 135.30 (+0.61%)
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 135.30 (+0.61%)
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 135.30 (+0.61%)
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 135.30 (+0.61%)
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced...

RVMD : 135.30 (+0.61%)
Stocks Settle Higher in Hopes for an Agreement to End the Iran War

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.06%. June E-mini S&P...

IDYA : 30.73 (+0.10%)
AVGO : 422.76 (+0.67%)
INTU : 395.95 (+3.30%)
SNDK : 989.90 (+6.16%)
SRE : 93.20 (-0.76%)
$IUXX : 27,303.67 (+1.95%)
ZNM26 : 111-070s (+0.15%)
ESM26 : 7,194.75s (+0.72%)
QCOM : 148.85 (+11.12%)
STX : 586.25 (-0.23%)
BBY : 60.45 (-1.71%)
$DOWI : 49,230.71 (-0.16%)
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced...

RVMD : 135.30 (+0.61%)
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?

Revolution Medicines stock rallies on impressive daraxonrasib Phase 3 results. Here’s why RVMD shares may sustain the momentum moving forward.

MRK : 111.90 (-2.37%)
ABBV : 198.71 (-1.11%)
RVMD : 135.30 (+0.61%)
Stocks Recover as Oracle Leads Software Companies Higher

The S&P 500 Index ($SPX ) (SPY ) today is up +0.09%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.16%. June E-mini S&P futures (ESM26...

ALK : 41.59 (+1.04%)
UAL : 93.00 (+1.92%)
IDYA : 30.73 (+0.10%)
INTU : 395.95 (+3.30%)
SNDK : 989.90 (+6.16%)
$IUXX : 27,303.67 (+1.95%)
ZNM26 : 111-070s (+0.15%)
ESM26 : 7,194.75s (+0.72%)
NCLH : 18.51 (+0.49%)
BBY : 60.45 (-1.71%)
$DOWI : 49,230.71 (-0.16%)
SPY : 713.94 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 144.93
2nd Resistance Point 141.69
1st Resistance Point 138.49
Last Price 135.30
1st Support Level 132.05
2nd Support Level 128.81
3rd Support Level 125.61

See More

52-Week High 155.70
Last Price 135.30
Fibonacci 61.8% 109.21
Fibonacci 50% 94.85
Fibonacci 38.2% 80.49
52-Week Low 34.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.